735 related articles for article (PubMed ID: 28580511)
21. Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kappaB ligand levels in women with established osteoporosis treated with teriparatide.
Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Pavlidou V; Koukoulis G; Avramidis A
Eur J Endocrinol; 2008 Mar; 158(3):411-5. PubMed ID: 18299476
[TBL] [Abstract][Full Text] [Related]
22. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
[TBL] [Abstract][Full Text] [Related]
23. Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
Stuss M; Sewerynek E; Król I; Stępień-Kłos W; Jędrzejczyk S
Endokrynol Pol; 2016; 67(2):174-84. PubMed ID: 26884284
[TBL] [Abstract][Full Text] [Related]
24. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
[TBL] [Abstract][Full Text] [Related]
25. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
26. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
27. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
[TBL] [Abstract][Full Text] [Related]
28. Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.
Fernández-García D; Muñoz-Torres M; Mezquita-Raya P; de la Higuera M; Alonso G; Reyes-García R; Ochoa AS; Ruiz-Requena ME; Luna JD; Escobar-Jiménez F
J Endocrinol Invest; 2008 May; 31(5):416-21. PubMed ID: 18560259
[TBL] [Abstract][Full Text] [Related]
29. Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma.
Ozer FF; Dagdelen S; Erbas T
Horm Metab Res; 2018 Jul; 50(7):562-567. PubMed ID: 29895074
[TBL] [Abstract][Full Text] [Related]
30. Effects of Curcumin on Bone Loss and Biochemical Markers of Bone Turnover in Patients with Spinal Cord Injury.
Hatefi M; Ahmadi MRH; Rahmani A; Dastjerdi MM; Asadollahi K
World Neurosurg; 2018 Jun; 114():e785-e791. PubMed ID: 29567290
[TBL] [Abstract][Full Text] [Related]
31. Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.
Mansour A; Aboeerad M; Qorbani M; Hashemi Taheri AP; Pajouhi M; Keshtkar AA; Larijani B; Mohajeri-Tehrani MR; Ganji MR
BMC Nephrol; 2018 Jul; 19(1):172. PubMed ID: 29996796
[TBL] [Abstract][Full Text] [Related]
32. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
[TBL] [Abstract][Full Text] [Related]
33. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system in patients with beta-thalassemia major.
Angelopoulos NG; Goula A; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Malaktari S; Athanasiou V; Tolis G
J Bone Miner Metab; 2007; 25(1):60-7. PubMed ID: 17187195
[TBL] [Abstract][Full Text] [Related]
34. Loss of lower extremity bone mineral density 1 year after denosumab is discontinued in persons with subacute spinal cord injury.
Cirnigliaro CM; La Fountaine MF; Parrott JS; Kirshblum SC; Sauer SJ; Shapses SA; McClure IA; Bauman WA
Osteoporos Int; 2023 Apr; 34(4):741-748. PubMed ID: 36735054
[TBL] [Abstract][Full Text] [Related]
35. Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study.
Nakamura Y; Kamimura M; Ikegami S; Mukaiyama K; Uchiyama S; Taguchi A; Kato H
BMC Endocr Disord; 2015 Dec; 15():81. PubMed ID: 26666998
[TBL] [Abstract][Full Text] [Related]
36. Denosumab for the Treatment of Mastocytosis-Related Osteoporosis: A Case Series.
Orsolini G; Gavioli I; Tripi G; Viapiana O; Gatti D; Idolazzi L; Zanotti R; Rossini M
Calcif Tissue Int; 2017 Jun; 100(6):595-598. PubMed ID: 28229176
[TBL] [Abstract][Full Text] [Related]
37. Changes in serum RANKL and OPG with sexual development and their associations with bone turnover and bone mineral density in a cohort of girls.
Lucas R; Ramos E; Prata M; Rodrigues AM; Costa L; Severo M; Canhão H; Fonseca JE; Barros H
Clin Biochem; 2014 Aug; 47(12):1040-6. PubMed ID: 24769277
[TBL] [Abstract][Full Text] [Related]
38. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.
Jørgensen L; Vik A; Emaus N; Brox J; Hansen JB; Mathiesen E; Vestergaard P
Osteoporos Int; 2010 Jun; 21(6):931-8. PubMed ID: 19701599
[TBL] [Abstract][Full Text] [Related]
39. Regulatory effect of parathyroid hormone on sRANKL-osteoprotegerin in hemodialysis patients with renal bone disease.
Doumouchtsis K; Perrea D; Doumouchtsis S; Tziamalis M; Poulakou M; Vlachos I; Kostakis A
Ther Apher Dial; 2009 Feb; 13(1):49-55. PubMed ID: 19379170
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the evolution of cortical and trabecular bone compartments in the proximal femur after spinal cord injury by 3D-DXA.
Gifre L; Humbert L; Muxi A; Del Rio L; Vidal J; Portell E; Monegal A; Guañabens N; Peris P
Osteoporos Int; 2018 Jan; 29(1):201-209. PubMed ID: 29043391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
